| Upcoming events on SEAGEN INC. |
|
| 12/05/20 | | American Society of Hematology Meeting |
| 02/11/21 | | FY 2020 Earnings Release (Projected) |
| 04/29/21 | | Q1 2021 Earnings Release (Projected) |
| 07/29/21 | | Interim 2021 Earnings Release (Projected) |
|
| Past events on SEAGEN INC. |
|
| 11/16/20 | 10:00am | | R&D Day |
| 11/11/20 | | Society of Immunotherapy of Cancer Meeting - Abstract No. - #250 |
| 11/11/20 | | Society of Immunotherapy of Cancer Meeting - Abstract No. - #438 |
| 11/11/20 | | Society of Immunotherapy of Cancer Meeting - Abstract No. - #323 |
|
| Upcoming sector events for SEAGEN INC. |
|
|
| |
|
| Past sector events for SEAGEN INC. |
|
|
|
|
|
| Annual results | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 (e) |
Sales
M $ |
Released
Forecast
Spread | 337
332
1,5% | 418
419
-0,10% | 482
482
0,00% | 655
644
1,7% | 917
846
8,4% |
2 155
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread | -106
-103
-3,7% | -125
-122
-2,2% | -172
-199
14% | -234
-212
-10% | -197
-246
20% |
559
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | -121
-123
2,1% | -143
-135
-5,9% | -196
-215
9,1% | -260
-237
-9,7% | -221
-266
17% |
577
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | -120
-121
0,83% | -140
-133
-5,3% | -159
-128
-24% | -246
-170
-45% | -159
-261
39% |
596
|
Net income
M $ |
Released
Forecast
Spread | -120
-122
1,0% | -140
-136
-3,3% | -126
-129
3,0% | -223
-172
-29% | -159
-262
39% |
588
|
EPS
$ |
Released
Forecast
Spread | -0,93
-0,96
2,8% | -1,00
-0,96
-4,7% | -0,88
-0,90
2,3% | -1,41
-1,11
-27% | -0,96
-1,59
40% |
3,26
| | Announcement Date | 02/09/2016 | 02/09/2017 | 02/06/2018 | 02/07/2019 | 02/06/2020 | |
|
|
|
| Quarterly results | 2018 Q2 | 2018 Q3 | 2018 Q4 | 2019 Q1 | 2019 Q2 | 2019 Q3 | 2019 Q4 | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 (e) | 2021 Q1 (e) | 2021 Q2 (e) | 2021 Q3 (e) | 2021 Q4 (e) |
Sales
M $ |
Released
Forecast
Spread | 170
141
21% | 169
167
1,5% | 175
164
6,4% | 195
187
4,3% | 218
190
15% | 213
212
0,67% | 290
219
32% | 235
208
13% | 278
257
8,2% | 1 062
487
118% |
582
|
377
|
403
|
442
|
481
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread | -23,5
-53,0
56% | -40,4
-43,0
6,1% | -83,3
-49,0
-70% | -48,7
-52,0
6,4% | -33,7
-54,2
38% | -85,5
-47,7
-79% | -28,8
-101
71% | -106
-153
30% |
| 648
610
6,3% |
|
|
|
|
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | -30,3
-60,2
50% | -45,6
-43,9
-3,7% | -90,3
-66,4
-36% | -53,6
-49,3
-8,8% | -38,7
-67,5
43% | -89,8
-62,6
-43% | -38,4
-86,4
56% | -112
-130
13% | -94,0
-117
20% | 638
98,6
547% |
153
|
-41,5
|
-28,1
|
-1,54
|
16,4
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | 76,3
-59,7
228% | -67,4
-42,8
-58% | -143
-65,2
-120% | -13,3
-50,6
74% | -79,2
-64,1
-24% | -91,9
-59,8
-54% | 25,8
-79,9
132% | -168
-128
-31% | -21,2
-110
81% | 639
125
411% |
155
|
-41,4
|
-28,0
|
-1,45
|
16,5
|
Net income
M $ |
Released
Forecast
Spread | 76,3
-60,7
226% | -67,4
-44,4
-52% | -120
-68,2
-76% | -13,3
-50,0
73% | -79,2
-63,8
-24% | -91,9
-59,1
-56% | 25,8
-80,7
132% | -168
-128
-32% | -21,2
-105
80% | 636
92,6
587% |
150
|
-41,4
|
-28,0
|
-7,97
|
9,25
|
EPS
$ |
Released
Forecast
Spread | 0,47
-0,38
222% | -0,42
-0,28
-52% | -0,75
-0,43
-73% | -0,08
-0,32
75% | -0,49
-0,39
-27% | -0,55
-0,36
-55% | 0,14
-0,48
129% | -0,98
-0,75
-30% | -0,12
-0,60
80% | 3,50
0,24
1 379% |
0,82
|
-0,25
|
-0,17
|
-0,04
|
0,06
| | Announcement Date | 07/26/2018 | 10/25/2018 | 02/07/2019 | 04/25/2019 | 07/16/2019 | 10/29/2019 | 02/06/2020 | 04/30/2020 | 07/30/2020 | 10/29/2020 | | | | | |
|
Financial data source
© 2020 S&P Global Market Intelligence
|
|
© 2020 Factset
|
|
|
|
Wall Street closes broadly higher on deal news, vaccine hopes |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
Previous period
